MKI67 and neuroendocrine carcinoma: Interestingly, in patients with NEC, defined as Ki67 > 20%, who received platinum etoposide chemotherapy in the NORDIC NEC study, the ORR was lower in those with Ki67 < 55% than those with a Ki67 ≥ 55% [5].